



US007326708B2

(12) **United States Patent**
Cypes et al.

(10) **Patent No.:** **US 7,326,708 B2**
(45) **Date of Patent:** **Feb. 5, 2008**

(54) **PHOSPHORIC ACID SALT OF A
DIPEPTIDYL PEPTIDASE-IV INHIBITOR**

(75) Inventors: **Stephen Howard Cypes**, Santa Clara,
CA (US); **Alex Minhua Chen**,
Metuchen, NJ (US); **Russell R. Ferlita**,
Westfield, NJ (US); **Karl Hansen**,
Atlantic Highlands, NJ (US); **Ivan Lee**,
Piscataway, NJ (US); **Vicky K. Vydra**,
Fair Lawn, NJ (US); **Robert M.**
Wenslow, Jr., East Windsor, NJ (US)

(73) Assignee: **Merck & Co., Inc.**, Rahway, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 657 days.

(21) Appl. No.: **10/874,992**

(22) Filed: **Jun. 23, 2004**

(65) **Prior Publication Data**

US 2005/0032804 A1 Feb. 10, 2005

Related U.S. Application Data

(60) Provisional application No. 60/482,161, filed on Jun.
24, 2003.

(51) **Int. Cl.**
A61K 31/495 (2006.01)
C07D 471/04 (2006.01)

(52) **U.S. Cl.** **514/249**; 544/350

(58) **Field of Classification Search** 514/249;
544/350

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,479,692 B1 * 11/2002 Ekwuribe et al. 558/413
6,699,871 B2 3/2004 Edmondson et al.
2003/0100563 A1 5/2003 Edmondson et al.
2006/0287528 A1 * 12/2006 Wenslow et al. 544/350
2007/0021430 A1 * 1/2007 Chen et al. 514/249

FOREIGN PATENT DOCUMENTS

WO WO 2005/072530 A1 8/2005
WO WO 2006/033848 A1 3/2006

OTHER PUBLICATIONS

Edmondson, S.D., Drug Data Report, vol. 25, No. 3, pp. 245-246
(2003).

Database Prous DDR Online—Database Accession No. 2003: 3561.

* cited by examiner

Primary Examiner—James O. Wilson

Assistant Examiner—Ebenezer Sackey

(74) *Attorney, Agent, or Firm*—Philippe L. Durette;
Catherine D. Fitch

(57) **ABSTRACT**

The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.

24 Claims, 5 Drawing Sheets